Kirby McInerney LLP Reminds Metagenomi Inc. (MGX) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Metagenomi, Inc. for allegedly misleading statements made during its IPO, particularly regarding its collaboration with Moderna, which was terminated shortly after the IPO [1][3]. Company Overview - Metagenomi, Inc. conducted its IPO on February 12, 2024, selling approximately 6.25 million shares at $15 per share [2]. - The company positioned itself as a "genetic medicines company" with a longstanding relationship with Moderna, a leading Covid-19 vaccine company [3]. Recent Developments - On May 1, 2024, Metagenomi announced the termination of its collaboration with Moderna, leading to a significant drop in its share price from $7.04 to $6.17, a decline of $0.87 or 12.4% [2]. Legal Proceedings - Investors who acquired Metagenomi securities during the class period from February 9, 2024, to May 1, 2024, have until November 25, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1].